1. Scrip
  2. >>Business

Blow To Genmab As It Is Set To Lose Darzalex Royalties Sooner Than Hoped

As Arbitration Disappoints

 
• By Ayisha Sharma

The Danish firm will stop receiving royalties on Darzalex after 2030 having has lost on two issues heard at an arbitration tribunal, in a significant blow to its finances.

Law mallet and a stack of money
Darzalex Made Over $6bn In 2021 Sales • Source: Alamy

Genmab A/S will lose its lucrative royalty stream from the multiple myeloma blockbuster Darzalex sooner than it had hoped after it lost to Johnson & Johnson on two matters at arbitration, raising concerns for the firm’s future finances.

Darzalex (daratumumab), an anti-CD38 monoclonal antibody (mAB), was developed under a years old agreement between the firms under which Genmab...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Business

More from Scrip

Pipeline Watch: Seven Approvals And Five Phase III Readouts

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Indegene Exec On DTP Distribution As A ‘Tactical Solution’, Feasibility Of MFN Model

 
• By Anju Ghangurde

Senior Indegene executive William Lobb talks about complexities of the direct-to-patient distribution model in the US and underlines that it isn’t a comprehensive healthcare fix. Feasibility of MFN pricing and why it may be “catastrophic” to the industry were some of the other topics discussed.

Quick Listen: Scrip’s Five Must-Know Things

 
• By Ian Haydock

In this week's episode: a look at the likely top drugs in 2030; Lilly CEO advocates US/Europe pricing rebalance; Insmed sees $5bn-plus market for Brinsupri; royalty deals go mainstream; Phase III win sets stage for Epkinly label expansion.